{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:54Z","timestamp":1793332614669,"version":"4.5.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 78-year-old man with multiple squamous cell carcinomas of the skin underwent <jats:sup>18<\/jats:sup>F-FDG-PET\/CT for restaging after 4 cycles of cemiplimab. The scan showed new disseminated FDG-avid skin lesions. Dermatologic examination and biopsy revealed bullous pemphigoid. Discontinuation of cemiplimab and treatment with corticosteroids led to clinical improvement, after which treatment with cemiplimab was resumed. A broad spectrum of inflammatory adverse events can occur in patients treated with immune checkpoint inhibitors, and FDG avidity of these lesions may mimic metastases. Knowledge of such imaging pitfalls is essential for interpreting <jats:sup>18<\/jats:sup>F-FDG-PET\/CT, particularly if they occur in the same organ as the primary tumor.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003894","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T22:10:54Z","timestamp":1631311854000},"page":"185-186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid"],"prefix":"10.1097","volume":"47","author":[{"given":"Hannes","family":"Gr\u00fcnig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan M.","family":"Skawran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"N\u00e4geli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivko","family":"Kamarachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Huellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1535-7163.MCT-16-0665","article-title":"Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 Knock-in mice","volume":"16","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/RLU.0000000000002408","article-title":"FDG PET\/CT course of pembrolizumab-associated multiorgan sarcoidosis","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000001758","article-title":"Nivolumab-induced development of pulmonary sarcoidosis in renal cell carcinoma","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/RLU.0000000000002779","article-title":"18F-FDG PET\/CT of multiorgan sarcoid-like reaction during anti-PD-1 treatment for melanoma","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/RLU.0000000000001981","article-title":"Superior pituitary border analysis in immunotherapy-induced hypophysitis","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/RLU.0000000000003251","article-title":"Pembrolizumab exacerbates thyroid diseases shown on FDG PET\/CT","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1097\/RLU.0000000000002549","article-title":"Pneumonitis related to melanoma immunotherapy","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/RLU.0000000000002707","article-title":"Nivolumab-induced pneumonitis in patient with metastatic melanoma showing complete remission on 18F-FDG PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/RLU.0000000000003306","article-title":"Pembrolizumab-induced thyroiditis and colitis-presentation and resolution on serial FDG PET\/CT","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/RLU.0000000000002692","article-title":"Focal immunotherapy-induced pancreatitis mimicking metastasis on FDG PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:07:29Z","timestamp":1750536449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003894"}},"subtitle":["A Possible Pitfall in 18F-FDG PET\/CT"],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003894","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}